Five things for pharma marketers to know: Tuesday, February 21, 2017


1. The drug industry doesn't plan to walk away from the potential of a market for treatments for Alzheimer's diseases, despite the challenges of bringing such a drug to market, and investors may agree. Even after Eli Lilly's shares fell 10% after a clinical-trial failure, they have since recovered. (WSJ)

2. Few new drugs are being developed for diabetes, compared to treatments being developed for cancer and rare diseases. Most diabetes drugs that are in late-stage trials are improved versions of existing treatments. (Stat)

3. Trevena said certain doses of its experimental opioid painkiller oliceridine were as effective as morphine in two late-stage clinical studies. The drug outperformed a placebo in reducing pain in two trials, but only two out of three doses were as effective as morphine. (Reuters)

4. The FDA issued a complete response letter to Amphastar Pharmaceuticals for its intranasal version of naloxone, which is the emergency treatment for an opioid overdose treatment. (Reuters)

5. AstraZeneca sold the U.S. and Canada rights to its cancer drug Zoladex to TerSera Therapeutics. The drugmaker will pay $250 million in an upfront payment to AstraZeneca. (PMLive)